Targeted Drug Prolongs Survival in Breast Cancer Patient Group
October 21, 2025
October 21, 2025
LONDON, England, Oct. 21 -- The Royal Marsden National Health Service Foundation Trust issued the following news:
* * *
Targeted drug prolongs survival in breast cancer patient group
Patients with HR+ and HER2- node positive high-risk early breast cancer experience improved long term overall survival seven years on following two years of taking a targeted drug alongside standard hormone therapy, according to research presented at ESMO.
The seve . . .
* * *
Targeted drug prolongs survival in breast cancer patient group
Patients with HR+ and HER2- node positive high-risk early breast cancer experience improved long term overall survival seven years on following two years of taking a targeted drug alongside standard hormone therapy, according to research presented at ESMO.
The seve . . .